Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with radiotherapy in soft-tissue sarcoma
NCT02787642Phase 1Completed
- Sponsor
- Institut Bergonié
- Start
- Jan 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in soft tissue sarcoma (STS), sponsored by Institut Bergonié. Primary endpoint: Maximum Tolerated Dose at 14 weeks. Started Jan 2016; status: completed.
02
Drugs
olaparib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02787642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787642.